Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News
Share Gainers
Here are the top 10 ASX 200 shares today
Broker Notes
Bell Potter says these are the best ASX shares to buy in October
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
These 6 shares are being kicked out of the ASX 200 index this month
Healthcare Shares
3 ASX healthcare stocks that have more than doubled in a year
Share Gainers
3 ASX All Ords shares up 250% to 750% in a year
Share Gainers
Why Cooper Energy, Medibank, NAB, and Neuren shares are charging higher today
Share Gainers
Why Azure Minerals, Global Lithium, Mesoblast, and Neuren shares are racing higher
Healthcare Shares
Why is the Neuren Pharmaceuticals share price rocketing 26% on Friday?
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
NEU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Apr 2026 | $12.46 | $0.19 | 1.55% | 321,185 | $12.12 | $12.66 | $11.98 |
| 29 Apr 2026 | $12.27 | $0.34 | 2.85% | 299,700 | $11.94 | $12.42 | $11.84 |
| 28 Apr 2026 | $11.93 | $-0.27 | -2.21% | 347,557 | $12.08 | $12.12 | $11.68 |
| 27 Apr 2026 | $12.20 | $-0.13 | -1.05% | 170,555 | $12.33 | $12.39 | $12.08 |
| 24 Apr 2026 | $12.33 | $0.15 | 1.23% | 283,618 | $12.15 | $12.33 | $12.01 |
| 23 Apr 2026 | $12.18 | $0.04 | 0.33% | 312,591 | $12.00 | $12.43 | $11.91 |
| 22 Apr 2026 | $12.14 | $-0.31 | -2.49% | 237,860 | $12.40 | $12.40 | $12.12 |
| 21 Apr 2026 | $12.45 | $-0.03 | -0.24% | 213,023 | $12.56 | $12.64 | $12.37 |
| 20 Apr 2026 | $12.48 | $-0.01 | -0.08% | 202,141 | $12.64 | $12.77 | $12.45 |
| 17 Apr 2026 | $12.49 | $0.01 | 0.08% | 254,622 | $12.34 | $12.52 | $12.33 |
| 16 Apr 2026 | $12.48 | $-0.01 | -0.08% | 285,507 | $12.65 | $12.66 | $12.33 |
| 15 Apr 2026 | $12.49 | $0.13 | 1.05% | 414,922 | $12.42 | $12.71 | $12.39 |
| 14 Apr 2026 | $12.36 | $0.13 | 1.06% | 277,046 | $12.51 | $12.67 | $12.34 |
| 13 Apr 2026 | $12.23 | $-0.29 | -2.32% | 206,401 | $12.25 | $12.35 | $12.01 |
| 10 Apr 2026 | $12.52 | $-0.06 | -0.48% | 247,703 | $12.30 | $12.61 | $12.28 |
| 09 Apr 2026 | $12.58 | $-0.42 | -3.23% | 252,921 | $12.70 | $12.89 | $12.49 |
| 08 Apr 2026 | $13.00 | $0.70 | 5.69% | 489,697 | $12.73 | $13.22 | $12.73 |
| 07 Apr 2026 | $12.30 | $0.27 | 2.24% | 247,337 | $12.25 | $12.58 | $12.07 |
| 02 Apr 2026 | $12.03 | $-0.31 | -2.51% | 436,301 | $12.38 | $12.40 | $11.83 |
| 01 Apr 2026 | $12.34 | $0.53 | 4.49% | 482,680 | $12.04 | $12.35 | $11.99 |
| 31 Mar 2026 | $11.81 | $0.18 | 1.55% | 518,165 | $11.37 | $12.08 | $11.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Mar 2026 | Joseph(Joe) Basile | Buy | 12,300 | $151,782 |
On-market trade.
|
| 08 Sep 2025 | Jonathan (Jon) Pilcher | Sell | 398,207 | $7,964,140 |
On-market trade.
|
| 22 Jul 2025 | Jonathan (Jon) Pilcher | Exercise | 1,500,000 | $2,760,000 |
Conversion of securities. Repayment of loan for 1,500,000 Loan Funded Shares
previously held in trust by Neuren Trustee Limited, at $1.84 per share and conversion to Ordinary Shares. |
| 22 Jul 2025 | Jonathan (Jon) Pilcher | Buy | 1,500,000 | $2,760,000 |
Conversion of securities. Repayment of loan for 1,500,000 Loan Funded Shares
previously held in trust by Neuren Trustee Limited, at $1.84 per share and conversion to Ordinary Shares. |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Dianne Margaret Angus | Non-Executive Director | Jul 2018 |
Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has created numerous global industry partnerships to yield innovative and competitive medical, pharmaceutical and agricultural products. With over twenty five years' experience in ASX and NASDAQ listed companies, she has expertise in business development, capital raising and investor relations together with corporate governance and compliance capabilities.
|
| Mr Jonathan (Jon) Charles Pilcher | Chief Executive OfficerManaging Director | Aug 2013 |
Mr Pilcher has played a central role in all aspects of the company's R&D, commercial and corporate activities. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
|
| Dr Jenny Lee Harry | Non-Executive Director | Jul 2018 |
Dr Harry has experience in executive management of companies in the biotechnology and biopharmaceutical industry and is an accomplished CEO and Managing Director with experience in early-stage companies to develop and commercialise innovative products. She has served on Boards of a number of listed and unlisted companies.
|
| Mr Patrick Davies | Non-Executive DirectorNon-Executive Chairman | Jul 2018 |
Mr Davies held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
|
| Mr Joseph(Joe) Basile | Non-Executive Director | Mar 2023 |
Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia.
|
| Ms Lauren Frazer | Chief Financial OfficerCompany Secretary | Aug 2020 |
-
|
| Gerry Zhao | Chief Business Officer |
-
|
|
| Lauren Frazer | Chief Financial OfficerCompany Secretary |
-
|
|
| Liza Squires | Chief Medical Officer |
-
|
|
| Clive Blower | Chief Operations Officer |
-
|
|
| Daryl Dekarske | Chief Regulatory Officer |
-
|
|
| Larry Glass | Chief Science Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 22,145,477 | 17.50% |
| Citicorp Nominees Pty Limited | 13,834,099 | 10.93% |
| J P Morgan Nominees Australia Pty Limited | 10,413,515 | 8.23% |
| BNP Paribas Noms Pty Ltd | 5,238,479 | 4.14% |
| Cameron Richard Pty Ltd | 3,914,900 | 3.09% |
| Stuart Andrew Pty Ltd | 2,814,100 | 2.22% |
| Smithley Super Pty Ltd | 1,577,000 | 1.25% |
| Linwierik Super Pty Ltd | 1,560,000 | 1.23% |
| BNP Paribas Nominees Pty Ltd (i) | 1,520,378 | 1.20% |
| Jonathan Pilcher | 1,500,000 | 1.19% |
| Sharesies Australia Nominee Pty Limited | 1,323,965 | 1.05% |
| Southern Capital Limited | 1,103,947 | 0.87% |
| Mjhft Pty Ltd | 900,000 | 0.71% |
| Essex Castle Limited | 843,731 | 0.67% |
| First Colbyco Pty Ltd | 800,000 | 0.63% |
| BNP Paribas Nominees Pty Ltd | 714,490 | 0.56% |
| Dr Robin Lance Congreve | 641,637 | 0.51% |
| Emancipayte Pty Ltd | 463,151 | 0.37% |
| BNP Paribas Nominees Pty Ltd (ii) | 463,066 | 0.37% |
| Mr He Zhao | 424,600 | 0.34% |
